<p>格兰马克制药有限公司：</p>
<ul>
<li>与翰森制药达成独家协议</li>
<li>在多个地区获得阿莫雷替尼的独家权利</li>
<li>翰森制药将获得超过 10 亿美元的累计付款</li>
</ul>

翰森制药

<p>Glenmark Pharmaceuticals Ltd：与翰森制药达成独家协议，获得在多个地区对 Aumolertinib 的独家权利，翰森制药将获得累计超过 10 亿美元的付款</p>

<p>Glenmark Pharmaceuticals Ltd :</p>
<div class="lb-trans"><p>格兰马克制药有限公司：</p>
</div><ul>
<li>ENTERS EXCLUSIVE AGREEMENT WITH HANSOH PHARMA</li>
<li>SECURES EXCLUSIVE RIGHTS FOR AUMOLERTINIB IN MULTIPLE REGIONS</li>
<li>HANSOH PHARMA WILL RECEIVE PAYMENT CUMULATING TO OVER $1 BILLION</li>
</ul>
<div class="lb-trans"><ul>
<li>与翰森制药达成独家协议</li>
<li>在多个地区获得阿莫雷替尼的独家权利</li>
<li>翰森制药将获得超过 10 亿美元的累计付款</li>
</ul>
</div>

Glenmark Pharma 与翰森制药签署独家协议